FDA Panel Narrowly Backs Galleri Blood Test for 50 Cancers
Updated
Updated · The Washington Post · Sep 24
FDA Panel Narrowly Backs Galleri Blood Test for 50 Cancers
3 articles · Updated · The Washington Post · Sep 24
Summary
A divided FDA advisory panel on Wednesday narrowly endorsed Galleri, a blood-based screening test designed to detect signals linked to 50 cancers before symptoms appear.
The split vote reflected unresolved doubts about how well the test works, underscoring why Galleri has become one of the most controversial efforts in multi-cancer early detection.
The recommendation moves the test a step closer to market, but the FDA still must make the final approval decision.
The case is a key test for whether blood-based screening can open a less invasive new front in cancer detection beyond single-cancer exams.
With billions at stake, will regulators unleash a revolutionary cancer-spotting blood test before proving it actually saves lives?
Could a single blood draw revolutionize early cancer detection, or will it unleash a wave of false alarms and unnecessary procedures?
FDA Panel’s Historic 6-4 Vote on Galleri: The Promise, Pitfalls, and Future of Multi-Cancer Early Detection Blood Tests
Overview
The FDA advisory panel’s historic but cautious endorsement of the Galleri multi-cancer blood test marked a turning point in cancer screening. While clinical trials showed the test could greatly increase cancer detection, a major UK study failed to prove it reduces late-stage cancers, leading the panel to recommend Galleri only as a supplement to routine screenings. Without FDA approval, patients must pay out-of-pocket, but new legislation will require Medicare to cover approved tests for seniors starting in 2028. Despite excitement, concerns remain about false negatives, psychological distress from positive results, and the impact of high-profile trial setbacks on future investment and adoption.